Search

everythinglearnresearchcommunity

for

Search:↓

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

2-Deoxy-D-Ribose is discussed as a potential hair loss treatment, but skepticism exists due to lack of human testing. The original poster uses a combination of topical Minoxidil, oral Finasteride, topical RU58841, and other treatments, reporting some hair regrowth but not significant results.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.

The conversation discusses using a lipodermal solution for hair loss, with concerns about side effects from multiple active ingredients. Users mention experiences with minoxidil, finasteride, and dutasteride, noting side effects like brain fog and sexual issues.

The conversation discusses hair loss and the ineffectiveness of a treatment called pyrilutamide, with one user experiencing negative results and questioning the product's authenticity.

Ordering Pyrilutamide from Minoxidilmax to use as an experimental topical treatment for hair loss, with discussion of the carrier used in trials and encouragement from other users.

Brian Dye's theory links skeletal malocclusion type II to hair loss, suggesting it's a blood flow issue. Treatments mentioned include minoxidil, finasteride, and anti-inflammatory drugs like benaxoprofen.

A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.

The conversation discusses using Latanoprost for hair regrowth, with the original poster seeking advice on where to purchase it without a prescription. Users suggest alternatives like Triple Hair's TH-07, which includes Finasteride, Minoxidil, and Latanoprost, and Strut's Latanoprost with melatonin and caffeine.

The conversation discusses a new liposomal topical finasteride from Hasson and Wong, available in Canada and Italy, soon in the US, costing $40/month. It claims to reduce scalp DHT by 50% without affecting serum DHT, potentially benefiting those who can't tolerate oral finasteride or RU58841.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The conversation is about seeking recommendations for clinics in Los Angeles that offer dutasteride mesotherapy for hair loss treatment. The user is asking for experiences and suggestions from the community.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

The conversation is about hair regrowth or miniaturization after two months of using minoxidil and spironolactone. Specific treatments mentioned are minoxidil and spironolactone.

Someone's two-month progress using oral minoxidil (2.5mg ED) to treat hair loss, which has resulted in thicker eyebrows and eyelashes but no scalp changes or shedding.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

The conversation discusses using NAC and quercetin as supplements for hair loss, with some users also mentioning finasteride. NAC is highlighted for its potential benefits, but concerns about its safety and absorption are also raised.

The conversation discusses using topical Calcipotriol and Valproic Acid for hair loss, focusing on their mechanisms involving the VDR receptor and Wnt/beta-catenin pathway. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.

KX-826 is discussed as a hair loss treatment, with comparisons to finasteride. It is noted to be more expensive, harder to source, and generally used for stabilization rather than growth.

The conversation discusses a hair loss treatment formulation containing cyclosporin, minoxidil, and tacrolimus, and mentions ongoing research on hair color reversal. The treatment showed high efficacy in restoring hair color in trials with 40 to 50 people.

First people receive Pyrilutamide on March 19th, 2022 for hair loss treatment. Users discuss obtaining the drug, its patent, and potential group buys.

A 26-year-old male is using a combination of clomiphene, minoxidil, tadalafil, bupropion, and lisdexamfetamine to address low testosterone, ED, depression, and focus issues. He seeks input on the safety and efficacy of this regimen, which also includes magnesium, zinc, and fish oil supplements.

Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.

The conversation discusses a hair loss treatment regimen using Alfatradiol, Pyrilutamide, and Minoxidil. The user shares their current stack of these treatments.

AHK-cu peptides are discussed for hair growth, with users comparing them to GHK-cu peptides and sharing sources to buy. AHK-cu is noted as more expensive, and users express interest in finding cheaper, reliable vendors.

A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.

A user who was losing their hair and found an effective solution; they asked for opinions on it and discussed treatments such as Minoxidil, Finasteride, and RU58841, as well as SMP.

User seeks availability of Breezula and its delayed trials. Asks for success with similar topical antiandrogens like fluridil.